Rijswijk, 9 August 2018, Sustaining earlier momentum from its successful launches of generic versions of both Rosuvastatin and Atorvastatin earlier in 2018, DSM Sinochem Pharmaceuticals (DSP) has now introduced its generic Caspofungin anti-fungal drug product in the United Kingdom. Additional markets within the EU are scheduled to follow later in the year.

Casofungin is primarily used in the treatment of invasive candidiasis and aspergillosis, along with other fungal infections. DSP’s generic version is a concentrate powder for infusion solutions, produced in the form of single use vials.

Ongoing portfolio expansion

With the launch now of its first anti-fungal finished dosage formulation, DSP is actively expanding its drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. DSP can now offer finished drug products in statins, anti-fungals and antibiotics across its global network.

Business Unit Director for Drug Products at DSP, Lucas Wiarda stated: “With our third launch of a finished dosage drug product in 2018, I am extremely proud of the team at DSP and the successes we’ve enjoyed this year. Caspofungin is the ideal complement to our product line, which helps to move DSP forward in our goal of producing a full range of finished dosage products for our Active Pharmaceutical Ingredients (APIs).  Additionally, with Caspofungin we have a global dossier, allowing us worldwide access for production and sale in the coming years.”

With the introduction of Caspofungin finished dosage formulation into the marketplace, DSP continues to deliver on its brand promise to customers, with Quality via world-class, differentiated active pharmaceutical ingredients, Reliability through a secure supply chain for producing a finished dosage product, and Sustainability at the forefront of its drug product production, using patented enzymatic technology which ensures an unmatched eco-friendly production process.

DSP holds an electronic Common Technical Document (eCTD) dossier for Caspofungin finished dosage formulations (in 50 and 70 mg vials) requiring constant refrigerated storage between 2 and 8 degrees Celsius.